



Press release | Lund 2026-04-29

Coegin Pharma AB publishes Annual Report for 2025

Coegin Pharma AB (“Coegin” or the “Company”) today announces that the Annual Report for 2025 is available on the Company’s website, www.coeginpharma.com, and is also attached to this press release as a PDF. The Annual Report is available in both Swedish and English.

As previously announced, the Annual General Meeting will be held on May 21, 2026.

Material uncertainty related to going concern

The auditor draws attention to the section “Liquidity and financial position” on page 19 of the Annual Report, which indicates that the Company is expected to have liquidity into the third quarter of 2026. These events or conditions indicate that a material uncertainty exists that may cast significant doubt on the Company’s ability to continue as a going concern. The auditor’s opinion is not modified in respect of this matter.

Company comment

Following a directed share issue of approximately SEK 12.1 million after the end of the reporting period, the Company’s liquidity has been strengthened. Based on current assumptions, the Company expects its financial resources to extend into the third quarter of 2026.

The Company will continue to focus on improving operational cash flow during 2026, with the aim of achieving balanced cash flow in the second half of the year. In parallel, the Company is evaluating several options to address its short-term financing needs.

For further information, please contact:

Jens Eriksson, CEO, Coegin Pharma AB

Email: je@coeginpharma.com

About Coegin Pharma

Coegin Pharma is a Swedish innovation company developing and commercializing advanced cosmetic technologies for hair and skin. The company’s flagship innovation, Follicopeptide®, is a patented, clinically developed peptide technology targeting hair thinning. It is currently being introduced globally through selected partners and the company’s own brand platform. In parallel, Coegin is advancing NPP-4, a next-generation cosmetic peptide innovation designed to enhance skin tone without UV exposure or chemicals.

With scalable in-house production, established intellectual property, and a flexible commercial model, Coegin Pharma is positioned to bring differentiated, science-based products to the global cosmetics market.

Coegin Pharma’s share is listed on the NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.

For more information, including company updates and social media links, visit coeginpharma.com

Coegin Pharma AB

c/o Medicon Village

223 81 Lund, Sweden

Registration number

559078-0465

coeginpharma.com

info@coeginpharma.com

